Cited by 13Renal Diseases and GlomerulopathiesLipoproteins and Cardiovascular HealthLipid metabolism and disorders

Lipoprotein Glomerulopathy Associated with a Mutation in Apolipoprotein E

Open access
Magistroni, Riccardo, Bertolotti, Marco, Furci, Luciana, Fano, Rita Adriana, Leonelli, Marco, Pisciotta, Livia, Pellegrini, Elisa, Calabresi, Laura +2 more·2013·Clinical Medicine Insights: Case Reports

Abstract

Lipoprotein glomerulopathy is a pathological condition characterized by lipid accumulation in the glomerular capillaries that has been associated with the presence of rare mutants of apolipoprotein E (ApoE). We describe a 51-year-old Italian patient presenting Type III hyperlipidemia and proteinuria in whom renal biopsy showed capillary ectasia and intraluminal lipid deposits, suggesting the diagnosis of lipoprotein glomerulopathy. The patient, who had elevated plasma ApoE level, was found to be heterozygous for a mutation in ApoE (Arg150Cys), designated apoE MODENA . This mutation induces the formation of ApoE dimers that are detectable under non-reducing conditions. Treatment with hypolipidemic drugs did not result in a complete remission of the proteinuria and was accompanied by a slow but progressive worsening of renal function with the persistence of intracapillary lipid thrombi. The introduction of low-density lipoprotein aphaeresis combined with a more aggressive lipid lowering and antihypertensive therapy resulted in the remission of proteinuria and a substantial improvement of renal function. Switching from low-density lipoprotein aphaeresis to plasma filtration did not result in an equivalent control of renal damage. The patient died of intracranial hemorrhage during an acute episode of malignant hypertension.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4137/ccrep.s12209

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Worldwide, only 22 cases of LPG including this case have reported the results of more than one native kidney biopsy.

    “Worldwide, only 22 cases of LPG including this case have reported the results of more than one native kidney biopsy.14,15,29,32,44–49”

    From Lipoprotein Glomerulopathy, First Case Report from Canada (2022) · cites this paper as [29]

    The Case Report’s First biopsy and Second biopsy sections document more than one renal biopsy in this LPG patient, so the paper supports one case of the kind counted. It does not establish the worldwide total of 22 cases; the searched passages provide no such count. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • APOE-Okayama (R150G) and APOE-Modena (R150C) were located on the ε2 allele.

    “We found that both APOE‐Okayama (R150G; Kinomura et al., 2008) and APOE‐Modena (R150C; Magistroni et al., 2013; Russi et al., 2009) were located on the ε2 allele, while APOE allele of APOE‐Guangzhou (R150P) was not reported (Luo et al., 2008).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 9

  1. [2]Liberopoulos E Siamopoulos K Elisaf M Apolipoprotein E and renal disease Am J Kidney Dis 2004 43 2 223 33 14750087
  2. [3]Saito T Ishigaki Y Oikawa S Yamamoto TT Etiological significance if apolipoprotein E mutations in lipoprotein glomerulopathy Trend Cardiovasc Med 2002 12 67 70 11852253
  3. [4]Saito T Matsunaga A Oikawa S Impact of lipoprotein glomerulopathy on the relationship between lipids and renal disease Am J Kidney Dis 2006 47 199 211 16431249
  4. [5]Rovin BH Roncone D McKinley A Nadasdy T Korbet SM Schwartz MM APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy N Engl J Med 2007 357 24 2522 4 18077821
  5. [6]Meyrier A Dairou F Callard P Mougenot B Lipoprotein glomerulopathy: first case in a white European Nephrol Dial Transplant 1995 10 4 546 9 7624001
  6. [7]Russi G Furci L Leonelli M Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report J Med Case Reports 2009 3 9311 PMC2803834 20062740
  7. [8]Tsimihodimos V Elisaf M Lipoprotein glomerulopathy Curr Opin Lipidol 2011 22 4 262 9 21464714
  8. [9]Luo B Huang F Liu Q Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy Am J Nephrol 2008 28 2 347 53 18046082 PMC2785906
  9. [11]Xin Z Zhihong L Shijun L Successful treatment of patients with lipoprptein glomerulopathy by protein A immunoabsorption. A pilot sudy Nephrol Dial Transplant 2009 24 864 9 18840890

Cited by

Sorted by citations

Authors
Magistroni, R., Bertolotti, M., Furci, L., Fano, R. A., Leonelli, M., Pisciotta, L., Pellegrini, E., Calabresi, L., Bertolini, S., & Calandra, S.
Affiliations
  • University of Modena and Reggio Emilia (IT)
  • University of Genoa (IT)
  • University of Milan (IT)
Corresponding author
Magistroni, Riccardo
Venue
Clinical Medicine Insights: Case Reports
Published
2013-01
Volume
6
Pages
189-96
ISSN
1179-5476 (ISSN-L)
OpenAlex
W2081342940
Cited by
13
References
2
Citations by year
2024: 2 · 2022: 4 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 1 · 2014: 1
FWCI
0.51
Type
journal article
Language
en
Open access
Locations
  • Clinical Medicine Insights Case Reports (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
lipoprotein glomerulopathy, apolipoprotein E, type III hyperlipidemia, proteinuria, LDL apheresis, plasma filtration, lipid-lowering therapy, malignant hypertension, intracranial hemorrhage

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review